UK the first European market to launch oral Wegovy
The United Kingdom has become the first European market to commence the commercial rollout of oral Wegovy. Following authorisation by the Medicines and Healthcare products Regulatory Agency on June 11, 2026, private healthcare providers began dispensing the once daily semaglutide tablet on July 6. The launch introduces a needle free alternative to the dominant injectable GLP-1 therapies, specifically targeting the…
Novo Nordisk Commits €432m to expand Irish GLP-1 production
Danish multinational pharmaceutical company Novo Nordisk has announced a significant capital investment of €432 million to expand its manufacturing facility in Athlone, Ireland, specifically to ramp up production of oral GLP-1 treatments. The initiative, announced March 2, focuses on increasing capacity for the tablet version of its weight-loss drug, Wegovy, and is intended to serve markets outside the United States.…
Novo Nordisk agrees weight loss price drop with US Administration
Denmark-based global chronic disease specialist Novo Nordisk has announced an agreement with the U.S. Administration to lower Wegovy and Ozempic prices across Medicare Part D, Medicaid and cash channels starting 2026. In exchange, Medicare will pilot obesity-drug coverage and the company gains a three-year tariff exemption. Management pegs the change at a low-single-digit drag on 2026 global sales growth but…